Literature DB >> 23708057

The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.

Ranran Wang1, Chao Yu, Dezhang Zhao, Mingjun Wu, Zhu Yang.   

Abstract

A high expression of O-glycosylated proteins is one of the prominent characteristics of ovarian carcinoma cells associated with cell migration, which would be attributed to the upregulated expression of glycosyltransferases. Therefore, elucidating glycosyltransferases and their substrates may improve our understanding of their roles in tumor metastasis. In the present study, we reported that knockdown of polypeptide N-acetylgalactosaminyltransferase 14 (GALNT14) by small interfering RNA significantly suppressed the cell migration and altered cellular morphology. Immunoprecipitation and western blot analyses indicated that GALNT14 contributed to the glycosylation of transmembrane mucin 13 (MUC13), which was significantly higher in ovarian cancer cells compared with the normal/benign ovary tissues. Furthermore, interleukin-8 (IL-8), which could regulate the migration ability of epithelial ovarian cancer (EOC) cells, had no remarkable effect on the expression of GALNT14 and the tumor-associated carbohydrate epitope Tn antigen. In addition, extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor modulated the expression levels of GALNT14. Our findings provide evidence that GALNT14 may contribute to ovarian carcinogenesis through aberrant glycosylation of MUC13, but not through the IL-8 pathway. These data provide novel insights into understanding the function of MUC13 on neoplasm metastasis and may aid in the development of new anticancer drugs for EOC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708057     DOI: 10.3892/or.2013.2493

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Hongliang Liu; Jian Wang; Robert Yu; Sanjay Shete; Erich M Sturgis; Guojun Li; Kristina R Dahlstrom; Zhensheng Liu; Christopher I Amos; Qingyi Wei
Journal:  Cancer Res       Date:  2020-04-10       Impact factor: 12.701

Review 2.  Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer.

Authors:  Jos P M van Putten; Karin Strijbis
Journal:  J Innate Immun       Date:  2017-01-05       Impact factor: 7.349

3.  BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.

Authors:  Joanna C Hillman; Elena M Pugacheva; Carter J Barger; Sirinapa Sribenja; Spencer Rosario; Mustafa Albahrani; Alexander M Truskinovsky; Aimee Stablewski; Song Liu; Dmitri I Loukinov; Gabriel E Zentner; Victor V Lobanenkov; Adam R Karpf; Michael J Higgins
Journal:  Mol Cancer Res       Date:  2019-07-10       Impact factor: 6.333

4.  Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.

Authors:  Miao-Juei Huang; Rey-Heng Hu; Chih-Hsing Chou; Chia-Lang Hsu; Ya-Wen Liu; John Huang; Ji-Shiang Hung; I-Rue Lai; Hsueh-Fen Juan; Sung-Liang Yu; Yao-Ming Wu; Min-Chuan Huang
Journal:  Oncotarget       Date:  2015-03-20

Review 5.  Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer.

Authors:  Andréia Vasconcelos-Dos-Santos; Isadora A Oliveira; Miguel Clodomiro Lucena; Natalia Rodrigues Mantuano; Stephen A Whelan; Wagner Barbosa Dias; Adriane Regina Todeschini
Journal:  Front Oncol       Date:  2015-06-25       Impact factor: 6.244

6.  Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.

Authors:  Zhi-Qiang Wang; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Dimcho Bachvarov
Journal:  Oncotarget       Date:  2014-01-30

Review 7.  N-acetylgalactosaminyltransferases in cancer.

Authors:  Muhammad Ramzan Manwar Hussain; Daniel C Hoessli; Min Fang
Journal:  Oncotarget       Date:  2016-08-16

8.  GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.

Authors:  Tzu-Chi Lin; Syue-Ting Chen; Min-Chuan Huang; John Huang; Chia-Lang Hsu; Hsueh-Fen Juan; Ho-Hsiung Lin; Chi-Hau Chen
Journal:  Oncotarget       Date:  2017-06-27

9.  A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.

Authors:  Razan Sheta; Christina M Woo; Florence Roux-Dalvai; Frédéric Fournier; Sylvie Bourassa; Arnaud Droit; Carolyn R Bertozzi; Dimcho Bachvarov
Journal:  J Proteomics       Date:  2016-04-17       Impact factor: 4.044

Review 10.  Drug resistance related to aberrant glycosylation in colorectal cancer.

Authors:  Ninon Very; Tony Lefebvre; Ikram El Yazidi-Belkoura
Journal:  Oncotarget       Date:  2017-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.